Bill of Health
MAY 22, 2023
The selections feature topics ranging from an analysis of government and industry investments for recently approved drugs, to a discussion of court decisions on mifepristone, and an examination of the added therapeutic benefit associated with the top-selling brand-name drugs in Medicare. JAMA Health Forum. 2023 Apr 7;4(4):e230511.
Bill of Health
JUNE 26, 2023
Increased access to drug pricing data can inform innovation policy decisions on exclusivities, competition, and access for the pharmaceutical industry in general. On August 7, 2022, the US Senate passed the Inflation Reduction Act , which gives Medicare the power to negotiate prices of certain high-cost drugs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Health Populi
MARCH 11, 2021
health care, patient assistance programs, Medicare Advantage plans, and the bundling of proven high-value preventive services into the Affordable Care Act. In the case of Medicare Part D, the drug benefit, Chandra said, “If you’re sick enough to fall into the donut hole, you may have higher mortality.”
Health Populi
OCTOBER 28, 2019
patients’ negative views of the pharmaceutical industry in this study was the opioid epidemic. Over one-half of Americans blame pharmaceutical companies as most responsible for the opioid crisis, followed by physicians, whom 39% of health consumers blame, and patients, whom 38% of people blame. Exacerbating U.S.
HIT Consultant
SEPTEMBER 14, 2023
Samm Anderegg, Co-Founder & CEO at DocStation Early next year, the Centers for Medicare and Medicaid Services (CMS) will remove the application of retroactive DIR fees and move DIR fees to the point of sale instead. What opportunities will AI offer the pharmaceutical industry to make further progress concerning PBMs and their DIR fees?
HIT Consultant
OCTOBER 20, 2023
can be attributed to falls, including approximately six percent of Medicare and eight percent of Medicaid expenditures. Fornari co-founded and was the CEO and medical director of Dominion Diagnostics, one of the country’s leading pharmaceutical monitoring laboratories and served there from 1997 to 2011.
Fierce Healthcare
AUGUST 29, 2023
The Biden administration and federal regulators may be taking a victory lap following the unveiling of the Centers for Medicare & Medicaid Services’ (CMS') price negotiations list, but major pl | Critics of President Joe Biden's policies to rein in prices for 10 Medicare Part D drugs believe the policy is "draconian" and will (..)
Expert insights. Personalized for you.
157 
Let's personalize your content